CD28-specific immunomodulating antibodies: what can be learned from experimental models?
about
Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cellsAdvantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28Immunotherapeutic strategies in autoimmune uveitisAnti-CD28 Antibody-Initiated Cytokine Storm in Canines.Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production.Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domainCD28 negative T cells: is their loss our gain?Costimulation blockade: current perspectives and implications for therapy.Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade.Impact of Immune-Modulatory Drugs on Regulatory T Cell.Cytokines: The Good, the Bad, and the Deadly.Functional polymorphisms in CD86 gene are associated with susceptibility to pneumonia-induced sepsis.Reply to "Biologics in organ transplantation".First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28.Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival.IL-23 and IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation.FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft.CD28 blockade controls T cell activation to prevent graft-versus-host disease in primatesClinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritisPreclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody
P2860
Q27340853-CA1EA870-DC08-4164-8FC4-5BC1E39A7A0BQ33573593-A107013A-61AD-4474-B532-1903A41ECB10Q34274950-D13C3675-BB84-4DC8-91B8-E920E0E7D9A8Q35610659-3B4EEDA5-36C4-4EAE-96F5-4C163A3461DDQ36293855-4EB1BF23-6408-4AD7-90F3-0885AD3D4760Q36588716-70A6F1F5-A87E-4DD3-A472-FD667463CF58Q36950690-D588CDE1-E0F0-4EB2-AC98-5288DA93DF62Q38057977-C4BB96A2-8532-40A7-9AEF-3B3F9CB6CD32Q38237428-BEF1F0EC-9C6E-4A61-9A11-E7B79C3A27BFQ38918124-9AC260D6-BF98-4106-AC39-E63B3DC721CBQ39002175-01B0984F-A282-43EC-AA98-0C1A9DA24B2CQ41014829-4D7F76EB-14B2-4B85-9DCC-00F6C5017061Q46541185-30AD968D-6FD1-4C73-BB61-C44FC55EEB53Q48223745-B6025030-284C-4F0C-98BE-2D0B35B7BCEAQ50101803-8C9060EE-C231-41EC-94DB-88E700C47313Q50532113-CE040E2E-6DD6-46F9-91AB-D3315440E1FFQ51026715-489F12ED-A2AF-4ECF-805F-166D8F66B6FFQ56889641-8CA48591-BC43-488A-8346-984FB8770EF9Q56895232-701A2FD3-4014-45B4-930B-FA1D79B49213Q56897833-02A048A1-AEB3-421A-ABEC-C1BBDBB4E96A
P2860
CD28-specific immunomodulating antibodies: what can be learned from experimental models?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
CD28-specific immunomodulating antibodies: what can be learned from experimental models?
@en
CD28-specific immunomodulating antibodies: what can be learned from experimental models?
@nl
type
label
CD28-specific immunomodulating antibodies: what can be learned from experimental models?
@en
CD28-specific immunomodulating antibodies: what can be learned from experimental models?
@nl
prefLabel
CD28-specific immunomodulating antibodies: what can be learned from experimental models?
@en
CD28-specific immunomodulating antibodies: what can be learned from experimental models?
@nl
P2093
P2860
P1476
CD28-specific immunomodulating antibodies: what can be learned from experimental models?
@en
P2093
P2860
P304
P356
10.1111/J.1600-6143.2012.04032.X
P407
P577
2012-04-04T00:00:00Z